A Pan-Cancer Analysis of the Oncogenic Role of BCL7B: A Potential Biomarker for Prognosis and Immunotherapy

被引:3
作者
Yang, Dinglong [1 ]
Li, Hetong [1 ]
Chen, Yujing [2 ]
Li, Chunjiang [3 ]
Ren, Weiping [3 ]
Huang, Yongbo [3 ]
机构
[1] Shanxi Med Univ, Clin Med Coll 2, Taiyuan, Peoples R China
[2] Xi An Jiao Tong Univ, Sch Publ Hlth, Xian, Peoples R China
[3] Second Hosp Shanxi Med Univ, Dept Orthoped, Taiyuan, Peoples R China
关键词
BCL7B; TCGA; pan-cancer; prognosis; immune infiltration; bioinformatics; PD-1; BLOCKADE; CELLS; LANDSCAPE; LYMPHOMA; GENES; EXPRESSION; CHROMATIN; IMMUNITY;
D O I
10.3389/fgene.2022.906174
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Previous studies have partly explored the role of B-cell CLL/lymphoma 7 protein family member B (BCL7B) in tumorigenesis and development. However, the prognosis and immunoregulatory value of BCL7B in pan-cancer patients remains unclear.Methods: Through The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, the distinct expression of BCL7B gene in 33 tumors and adjacent normal tissues was analyzed. The Kaplan-Meier method (univariate Cox regression analysis and Kaplan-Meier curve) was used to identify the cancer types whose BCL7B gene expression was related to prognosis. The receiver operating characteristic (ROC) curve was used to elucidate the diagnosis value of BCL7B gene. Spearman's rank correlation coefficient was used to explore the relationship between BCL7B gene expression and immune cell infiltration, immune checkpoints, DNA methylation, DNA repair genes, immune-activating genes, immune-suppressing genes, immune subtypes, tumor mutation burden (TMB), and microsatellite instability (MSI). The Wilcoxon rank sum test and Kruskal-Wallis test were used to compare the expression of BCL7B gene in tumor tissues with different clinicopathological features. Gene set enrichment analysis (GSEA) was conducted to identify the tumor-related pathways in pan-cancer. The Human Protein Atlas (HPA) database was used to verify the BCL7B gene expression at the protein level.Results: High expression of BCL7B was associated with an inferior prognosis in glioblastoma multiforme (GBM), glioma (GBMLGG), kidney chromophobe (KICH), brain lower grade glioma (LGG), oral squamous cell carcinoma (OSCC), rectum adenocarcinoma (READ), and uveal melanoma (UVM). Low expression of BCL7B was associated with a poor prognosis in kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), skin cutaneous melanoma (SKCM), thyroid carcinoma (THCA), and sarcoma (SARC). The BCL7B gene expression had varying degrees of correlation with 24 immune cell subsets in 37 tumor environments such as adrenocortical carcinoma (ACC) and bladder urothelial carcinoma (BCLA). Spearman's rank correlation coefficient showed that BCL7B gene expression had different degrees of correlation with 47 immune checkpoints, 46 immune-activating genes, 24 immune-suppressing genes, 5 DNA repair genes, and DNA methylation, TMB, and MSI in 39 tumors. GSEA suggested that BCL7B was notably associated with cancer-related and immune-related pathways.Conclusion: In summary, BCL7B gene has a high diagnostic and prognostic value in pan-cancer and is related to the infiltration of 24 immune cell subsets in pan-cancer.
引用
收藏
页数:16
相关论文
共 50 条
[31]   Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy [J].
Tu, Zewei ;
Li, Kuangxun ;
Ji, Qiankun ;
Huang, Yuyang ;
Lv, Shigang ;
Li, Jingying ;
Wu, Lei ;
Huang, Kai ;
Zhu, Xingen .
BMC CANCER, 2023, 23 (01)
[32]   Comprehensive pan-cancer analysis of ACSS3 as a biomarker for prognosis and immunotherapy response [J].
Zhang, Zhanzhan ;
Yan, Hongshan ;
Tong, Hao ;
Guo, Kai ;
Song, Zihan ;
Jin, Qianxu ;
Zhao, Zijun ;
Zhao, Zongmao ;
Shi, Yunpeng .
HELIYON, 2024, 10 (15)
[33]   Pan-Cancer Analysis of CENPA as a Potential Prognostic and Immunological Biomarker in Human Cancer [J].
Hu, Zhongjiao ;
Zhang, Shutao ;
Yan, Xueling ;
Zheng, Lulu ;
Ding, Ke ;
Liu, Shanshan ;
Shi, Zheng .
CURRENT BIOINFORMATICS, 2022, 17 (07) :599-614
[34]   A pan-cancer cuproptosis signature predicting immunotherapy response and prognosis [J].
Zhu, Xiaojing ;
Zhang, Zixin ;
Xiao, Yanqi ;
Wang, Hao ;
Zhang, Jiaxing ;
Wang, Mingwei ;
Jiang, Minghui ;
Xu, Yan .
HELIYON, 2024, 10 (15)
[35]   An association between ATP7B expression and human cancer prognosis and immunotherapy: a pan-cancer perspective [J].
Zhang, Zhanzhan ;
Zhang, Aobo ;
Shi, Yunpeng ;
Zhao, Zijun ;
Zhao, Zongmao .
BMC MEDICAL GENOMICS, 2023, 16 (01)
[36]   Oncogenic role and potential regulatory mechanism of topoisomerase IIα in a pan-cancer analysis [J].
Wang, Xiaobo ;
Wang, Jinhua ;
Lyu, Li ;
Gao, Xin ;
Cai, Yinuo ;
Tang, Bo .
SCIENTIFIC REPORTS, 2022, 12 (01)
[37]   FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration [J].
Cai, Jiayang ;
Ye, Zhang ;
Hu, Yuanyuan ;
Wang, Yixuan ;
Ye, Liguo ;
Gao, Lun ;
Sun, Qian ;
Tong, Shiao ;
Sun, Zhiqiang ;
Yang, Ji'an ;
Chen, Qianxue .
FRONTIERS IN ONCOLOGY, 2022, 12
[38]   Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker [J].
Deng, Xinna ;
Wang, Yashu ;
Guo, Hao ;
Wang, Qian ;
Rao, Shuting ;
Wu, Haijiang .
CANCERS, 2023, 15 (21)
[39]   CCDC58 is a potential biomarker for diagnosis, prognosis, immunity, and genomic heterogeneity in pan-cancer [J].
Yang, Kai ;
Ma, Yan ;
Chen, Weigang ;
Liu, Lu ;
Yang, Zelong ;
He, Chaokui ;
Zheng, Nanbei ;
Liu, Xinyu ;
Cheng, Xin ;
Song, Junbo ;
Chen, Yong ;
Qiao, Hongyu ;
Zhang, Ruohan .
SCIENTIFIC REPORTS, 2024, 14 (01)
[40]   PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer [J].
Zhao, Qi ;
Zhang, Zhongwei ;
Wu, Yinfang .
ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2022, 52 (02) :185-195